Saturday, October 10, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleVentureBeat AI

Claude Code costs up to $200 a month. Goose does the same thing for free.

View original at venturebeat.com
VentureBeat AI - Enterprise Ai Title: Claude Code costs up to $200 a month. Goose does the same thing for free…
Opening lines of the source · VentureBeat AI · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The new rate limits affect fewer than five percent of users and target people running Claude Code continuously in the background, 24/7

    80% confidence
  • It's confusing and vague. When they say '24-40 hours of Opus 4,' that doesn't really tell you anything useful about what you're actually getting

    80% confidence
  • Your data stays with you, period

    80% confidence
  • I use Ollama all the time on planes — it's a lot of fun!

    80% confidence
  • You don't need to run the largest models to get excellent results

    80% confidence
  • When I say 'make this look modern,' Opus knows what I mean. Other models give me Bootstrap circa 2015

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Agentic Enterprise Software Consolidates: Big Platforms Push Autonomy While Startups Get Absorbed
Enterprise software is shifting toward autonomous, AI-agent-driven products. SAP (Autonomous Enterprise, Joule), Meta (a new Enterprise Platform led by ex-MongoDB CEO Chirantan Desai) and UiPath (raised guidance) are pushing from the top. Meanwhile AI-security and governance startups are being acquired (Fortinet–Virtue AI, Harvey–Guardrails AI, Tiny–Oso Cloud) and seed-stage agent companies keep raising capital (Dextr, Latitude, Groq). Investors such as Norwest's Sean Jacobsohn see finance and ERP back-office software as the easier area to disrupt. Trust and enforced governance are treated as preconditions for regulated sectors like finance, and AI is judged unreliable for calculations.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,365 source documents archived
Query this data → isubstrate.com